Navigation Links
AcelRx Pharmaceuticals to Host Investor Day on June 27, 2013
Date:6/21/2013

REDWOOD CITY, Calif., June 21, 2013 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, will host an Investor Day on Thursday, June 27, 2013, from 9:00 a.m. to 11:00 a.m. EDT (6:00 a.m. to 8:00 a.m. PDT) at the 21 Club, 21 West 53rd Street, New York, NY.

Members of the AcelRx management team will present insights on the Company's Sufentanil NanoTab PCA System Phase 3 clinical trial results and discuss plans related to hospital formulary adoption and commercialization. In addition, thought leaders who treat post-operative pain in the hospital setting will discuss their experience with and perspectives on the Sufentanil NanoTab PCA System. Breakfast will be served for meeting attendees from 8:00 a.m. to 9:00 a.m. and a link to the live webcast will be available on the Investors page of the Company's website at www.acelrx.com beginning at 9:00 a.m. EDT. An archive of the webcast will be available shortly after the event through the Investors page at www.acelrx.com.

About AcelRx Pharmaceuticals, Inc.

AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain.  AcelRx's lead product candidate, the Sufentanil NanoTab PCA System, is designed to solve the problems associated with post-operative intravenous patient-controlled analgesia which has been shown to cause harm to patients following surgery because of the side effects of morphine, the invasive IV route of delivery and the complexity of infusion pumps. The NanoTab System has
'/>"/>

SOURCE AcelRx Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. AcelRx Pharmaceuticals to Present at the UBS Global Healthcare Conference
2. AcelRx Pharmaceuticals Reports First Quarter 2013 Financial Results
3. AcelRx Pharmaceuticals to Hold First Quarter 2013 Financial Results Conference Call and Webcast on May 8, 2013
4. AcelRx Pharmaceuticals Presents Positive Clinical Data for the Sufentanil NanoTab PCA System at ASRA Medical Meeting
5. Top-line Data Show AcelRx Pharmaceuticals ARX-04 Achieves Primary Endpoint in Dose-Finding Phase 2 Clinical Trial
6. AcelRx Pharmaceuticals Reports Fourth Quarter and Full-Year 2012 Financial Results
7. AcelRx Pharmaceuticals to Hold Fourth Quarter 2012 Financial Results Conference Call and Webcast on March 12, 2013
8. AcelRx Top-line Data Show Primary Endpoint Achieved in Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Post-Operative Pain in Major Open Abdominal Surgery Patients
9. AcelRx Pharmaceuticals to Present at Two Upcoming Investor Conferences
10. AcelRx Pharmaceuticals Provides Clinical Trial Updates
11. AcelRx Appoints Adrian Adams to Board of Directors as Chairman
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... , December 17, 2014 Revenue and ... expenditure on research and development In the past ... revenue by two percent to EUR 4.287 billion (last year: ... by 14 percent to EUR 360 million. "Overall, 2013/14 was ... Michael Kaschke , President and CEO of Carl Zeiss ...
(Date:12/17/2014)...  Beamz Interactive, Inc. (OTCQB: BZIC), a leading ... that it has signed an agreement with RSL ... innovative prosthetic, orthotic and assistive technology products and ... RSL Steeper will promote and supply the Beamz ... within UK residential care facilities through its Assistive ...
(Date:12/17/2014)... Dec. 17, 2014  RXi Pharmaceuticals Corporation (NASDAQ: ... on discovering, developing and commercializing innovative therapies addressing ... completion of enrollment in its first Phase 2a ... observations confirmed the 1-month findings that were reported ... Logo - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO , ...
Breaking Medicine Technology:ZEISS Asserts its Position in Difficult Environment 2Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 2Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 2RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 4RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 5
... MYL ) today announced that its subsidiary Mylan ... and Drug Administration (FDA) for its Abbreviated New Drug Application ... mg, 10 mg, 15 mg, and 20 mg. This product ... ® , which is indicated for the treatment of schizophrenia ...
... Young Innovations, Inc. (NASDAQ: YDNT ) today announced sales ... Sales for the first quarter of 2012 were ... the first quarter of 2011. Income from operations increased 5.3% to ... in the first quarter of 2011. Net income increased 5.6% to ...
Cached Medicine Technology:Mylan Launches Generic Version of Zyprexa® Tablets 2Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012 2Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012 3Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012 4
(Date:12/17/2014)... 17, 2014 A group of 127 scientists ... today, in reaction to a recent statement by the center ... training and derogated the efficacy of all brain exercises. , ... the parts of the center’s statement critical of brain exercise ... had also overstated its case, in a document it had ...
(Date:12/17/2014)... 2014 Project Veritas is releasing a ... of MIT economist and Obamacare architect Jonathan Gruber to ... conducted the interview, which is being distributed on YouTube. ... intentional mislabeling in the Affordable Care Act in order ... two-hundred-and-fifty billion dollar per year tax grab. , “President ...
(Date:12/17/2014)... -- Poor students get more fruits and vegetables at school ... But, the opposite is true for students from wealthier families. ... school may give a healthy boost to poor students, diets, ... family income level, students all ate a similar amount of ... study was published recently in the journal Preventive Medicine ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. ... in America, and work commitment is a big reason why, ... killer," said Dr. Mathias Basner, an assistant professor of sleep ... School of Medicine. A time-use survey of nearly 125,000 ... the main activity exchanged for sleep. Short sleepers -- those ...
(Date:12/15/2014)... Main Street Dental Team ( http://www.MainStreetDentalTeam.com ), Unionville’s first ... study providing evidence on the impact of 100% pure ... Sufficient enough evidence already exists showing a negative link ... with the onset of tooth decay. One question that ... 100% fruit juice, meaning it is completely natural with ...
Breaking Medicine News(10 mins):Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 2Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 3Health News:Scientists to Stanford: Research Shows Brain Exercises Can Work 4Health News:Project Veritas: James O’Keefe Interviews the Man Who Discovered Jonathan Gruber Videos 2Health News:Poor Students Eat Healthier Foods at School, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3Health News:Main Street Dental Team, Unionville’s Most Innovative Dental Clinic, Comments on New Study Relating Pure Fruit Juice to Poor Oral Hygiene 2
... Australia, Fremantle, for the patients with type II diabetes, the ... if they self-monitor their blood glucose levels. ,Dr. ... the journal Diabetes Care, explained that they conducted their study ... the Fremantle Diabetes Study. It was reported that a total ...
... in Toronto will begin on Sunday, bringing together over 20,000 ... play a more active role in the battle with this ... hard around the world especially in sub-Saharan Africa which is ... that nearly 9 out of 10 children diagnosed with HIV/AIDS ...
... new study published in the September issue of the ... identified the genes //responsible for preserving cognition even at ... of Pittsburgh are the first to identify the genetic ... has been defined in many ways, however, we focused ...
... expect far more from the children than their ... to a study that has been published in ... are increasingly being expected to provide an adult-level ... professor in McMaster University's Department of Psychology, Neuroscience ...
... diagnosed with prostate cancer three years ago is now ... Hospital. ,In a statement released by the Tannadice ... his illness were released putting an end to the ... ,The new treatment began at Ninewells Hospital ...
... workers against any pandemic or influenza outbreak, South Australia ... Mr. John Hill said//. The fund would assist in ... would be necessary to fight a potential influenza outbreak. ... the outbreak was uncontrollable, nearly 25% of South Australians ...
Cached Medicine News:Health News:Study Finds No Benefits On Self Monitoring Blood Glucose levels 2Health News:Church to Have an Active Role in the Prevention of AIDS 2Health News:Genes And Aging 2Health News:Please Give Kids a Break!! 2
Achievement, available exclusively from Art Optical, is a unique RGP lens design with a patented junctionless back surface and a controlled edge lift....
... is designed using sophisticated lathing techniques, intrinsically ... lenses feature a center thickness of just ... all plus powered Thinsite lenses maintain a ... designs. The unique design eliminates stress points ...
... is a simultaneous vision lens ... Through a series of front ... LifeStyle Gp delivers up to ... its multi-aspheric center-distance design works ...
Boston Multivision design is manufactured in Boston ES material for early presbyope patients. Boston Multivision lens provides crisp, clear vision at near, intermediate, and far distances and excelle...
Medicine Products: